Press Releases

Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and Immunology

SAN DIEGO, March 08, 2018 — Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that a study titled “Human Factors Study in Untrained Adolescents Comparing Its Epinephrine Prefilled Syringe (Symjepi™) with EpiPen® Auto-Injector” was recently published in the Annals of Allergy, Asthma and Immunology.

SymjepiTM, a prefilled syringe containing epinephrine for the treatment of anaphylaxis, fared well when compared to the market leader in this published, peer-reviewed study. Human factor studies are very useful to test devices in order to approximate their correct or incorrect use in real situations and in different populations. A human factors study was conducted post-approval to compare the correct use of Symjepi™ compared to EpiPen® in untrained adolescents. Participants were aged 12 to 17 years old, had no familiarity with an epinephrine injector device (naïve) and were not trained during the study. There were 17 male and 17 female subjects with a mean age of 14.7 years.

The participants were randomized into two groups (cohorts) of 17. In the first cohort, participants were provided Symjepi™ devices and asked to imagine experiencing symptoms that required an immediate injection of epinephrine. After simulating an injection with Symjepi™ devices, participants were provided EpiPen® devices and asked to attempt a second injection. Participants in the second cohort were provided EpiPen® devices first, then asked to attempt a second injection with the Symjepi™ devices.

Among all injection attempts, there were no use errors for the Symjepi™ device (0/34). All 34 participants successfully completed all steps in order to simulate an epinephrine injection with the Symjepi™ device. However, a total of four errors (4/34) were observed for the EpiPen® with three of four incorrectly injecting their thumb. All four errors were considered critical use errors that could have a negative impact on the effective treatment of anaphylaxis.

The 12% error rate for participants attempting to use EpiPen® in this study was similar to the use error rate observed in another published study of untrained participants which had an 11% failure rate. It is noteworthy to understand why untrained adolescents were used in this study. This is the largest population of fatalities caused by anaphylaxis due to foods. Food allergies contribute to as many as 70% of all food related deaths. Therefore, proper use of epinephrine injection devices is of paramount importance in this age group.

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “This study demonstrates the ease of using Symjepi™. We believe Symjepi™ will provide a small, non-threatening, intuitive alternative to the market-leading auto-injectors.” Dr. Ronald Moss, Chief Medical Officer of Adamis, added, “The correct use of a device with epinephrine is critical to effectively treating a life-threatening episode. This prospective human factor study supports the ease and correct use of Symjepi™ for the acute treatment of anaphylaxis.”

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. The company’s first product, Symjepi™ (epinephrine) Injection 0.3mg, was approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’ product pipeline includes HFA metered dose inhaler and dry powder inhaler products for the treatment of bronchospasm and asthma.

The Company’s U.S. Compounding, Inc. (USC) subsidiary, which is registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act and the U.S. Drug Quality and Security Act, compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.

Adamis Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations, including, but not limited to the following statements: the status of anticipated presentations by the company at upcoming conferences; the company’s beliefs concerning the ability of its products and product candidates to compete successfully in the market; the company’s beliefs concerning the results of studies relating to Symjepi and user perceptions of Symjepi; and the company’s beliefs concerning the safety and effectiveness of its products and product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from those contemplated by these forward-looking statements. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s web site at Any forward-looking statement in this press release speaks only as of the date on which it is made. Except to the extent required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.


Mark Flather
Senior Director, Investor Relations
& Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951

Primary Logo

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit

Check this page for the most recent updates regarding the merger process.